Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00395967 · BASELINE

Baseline characteristics

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone · Source last updated 2015-05-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      5
    units
    Participants
groups
  1. description
    Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
    id
    BG000
    title
    All Patients
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.5
          value
          52.2
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          3
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      Caucasian
    param Type
    NUMBER
    title
    Race/Ethnicity, Customized
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Multiple Myeloma (MM)
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      Non-Hodgkin's lymphoma (NHL)
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Hodgkin's disease (HD)
    description
    One patient with HD was entered into the study even though there was no indication of MM or NHL (an inclusion criteria).
    param Type
    NUMBER
    title
    Disease Diagnosis
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      5
    units
    Participants
groups
  1. description
    Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
    id
    BG000
    title
    All Patients
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.5
          value
          52.2
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          3
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      Caucasian
    param Type
    NUMBER
    title
    Race/Ethnicity, Customized
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Multiple Myeloma (MM)
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      Non-Hodgkin's lymphoma (NHL)
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Hodgkin's disease (HD)
    description
    One patient with HD was entered into the study even though there was no indication of MM or NHL (an inclusion criteria).
    param Type
    NUMBER
    title
    Disease Diagnosis
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice